4.7 Article

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H. I. Andtbacka et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Editorial Material Oncology

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Review Oncology

New modalities of cancer treatment for NSCLC: focus on immunotherapy

Marianne Davies

CANCER MANAGEMENT AND RESEARCH (2014)

Editorial Material Oncology

When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

Geoffrey R. Oxnard et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)

Article Medicine, General & Internal

Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer

Suzanne L. Topalian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Editorial Material Oncology

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

James R. Anderson et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)